Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Ab&B Bio-Tech (中慧生物) Pre-IPO: A Shaky Story of Flu Vaccine Rising Star

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>China-Based vaccine biopharmaceutical company Ab&amp;B is looking to raise at least US$100 million via a Hong Kong listing. The joint book runners are CITIC and CMBI.</li>
<li>In our previous insight, we looked at the story that the company is trying to sell and the influenza vaccine market.</li>
<li>In this insight, we look at the latest updates in its PHIP filing.</li>
</ul>


China-Based vaccine biopharmaceutical company Ab&amp;B is looking to raise at least US$100 million via a Hong Kong listing. The joint book runners are CITIC and CMBI.
In our previous insight, we looked at the story that the company is trying to sell and the influenza vaccine market.
In this insight, we look at the latest updates in its PHIP filing.


Ab&B Bio-Tech (中慧生物) Pre-IPO: PHIP Updates Suggest Competition Intensifying